The 10-second takeaway
For the quarter ended March 31 (Q1), Amedisys beat slightly on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue improved slightly and GAAP earnings per share contracted significantly.
Margins dropped across the board.
Amedisys chalked up revenue of $370.8 million. The 12 analysts polled by S&P Capital IQ expected a top line of $366.6 million on the same basis. GAAP reported sales were 1.8% higher than the prior-year quarter's $364.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.22. The 12 earnings estimates compiled by S&P Capital IQ forecast $0.22 per share. GAAP EPS of $0.18 for Q1 were 66% lower than the prior-year quarter's $0.53 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.8%, 370 basis points worse than the prior-year quarter. Operating margin was 3.4%, 410 basis points worse than the prior-year quarter. Net margin was 1.5%, 270 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $370.3 million. On the bottom line, the average EPS estimate is $0.24.
Next year's average estimate for revenue is $1.49 billion. The average EPS estimate is $1.01.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 838 members out of 933 rating the stock outperform, and 95 members rating it underperform. Among 229 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 192 give Amedisys a green thumbs-up, and 37 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $12.10.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Amedisys prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Amedisys to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.